Vivoryon Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ulrich Dauer (57 yo)





Dr. Ulrich Dauer has been Chief Executive Officer and Chairman of the Management Board at Vivoryon Therapeutics N.V. (formerly known as Vivoryon Therapeutics AG) since May 01, 2018. He has been Chairman of...

CEO Compensation Analysis

Ulrich Dauer's Compensation vs Vivoryon Therapeutics Earnings
How has Ulrich Dauer's remuneration changed compared to Vivoryon Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019€530k€240k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018€163k€160k


Compensation vs Market: Insufficient data to establish whether Ulrich's total compensation is reasonable compared to companies of similar size in the Dutch market.

Compensation vs Earnings: Ulrich's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: VVY's management team is considered experienced (4.4 years average tenure).